Sakar Healthcare Ltd (SAKAR) — shareholding pattern, promoter holding, financials and share price
About Sakar Healthcare Ltd (SAKAR)
Sakar Healthcare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SAKAR and on the BSE under scrip code 538377. Its ISIN is INE732S01012.
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products [1]
Sakar Healthcare Limited is an India‑based integrated pharmaceutical manufacturer and CDMO offering API‑to‑FDF capabilities across oral solids, sterile injectables (liquids and lyophilised), oral liquids and oncology formulations, operating EU‑GMP and WHO‑GMP certified facilities and supplying global partners and own‑brand exports to 60+ countries.
Sakar has deliberately repositioned toward oncology as a value driver: the Bavla facility is EU‑GMP approved, vertically integrates API and finished dosage manufacturing, and currently lists 55 oncology molecules developed with 32 dossiers ready for launch and eleven marketing authorisations granted, signalling a step‑change in product complexity and margin profile.
Listed peers in Pharmaceuticals: Ind-Swift Laboratories Ltd, NGL Fine Chem Ltd, Hester Biosciences Ltd, Windlas Biotech Ltd, Amrutanjan Health Care Ltd, Jagsonpal Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹824.5 a share on 10 Jul 2026, Sakar Healthcare Ltd (SAKAR) was valued at a price-to-earnings ratio of 60.19x against an industry P/E of 36.41x and a price-to-book of 6.43x on a book value of ₹128.3 per share as of Mar 2025. Solomo computes return on equity of 10.68% and return on capital employed of 13.21% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 60.19x
- Industry P/E
- 36.41x
- P/B
- 6.43x
- EPS (TTM)
- ₹13.7
- Book value / share
- ₹128.3
- ROE
- 10.68%
- ROCE
- 13.21%
- ROA
- 7.34%
- Debt / equity
- 0.26x
- Dividend yield
- 0%
- EBITDA margin
- 28.28%
- 52-week range
- ₹311 – ₹889.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sakar Healthcare Ltd (SAKAR) reported revenue of ₹252 crore, net profit of ₹30 crore and earnings per share of ₹13.7. That compares with revenue of ₹178 crore and net profit of ₹18 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹71 crore and net profit ₹11 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 128 | 133 | 153 | 178 | 252 |
| Net profit (₹ cr) | 15 | 13 | 12 | 18 | 30 |
| EPS (₹) | 8.9 | 6.7 | 5.37 | 7.97 | 13.7 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 17.62% | 16.44% | 11.47% | 15.80% |
| Profit growth | 25.80% | 12.71% | 4.72% | 49.96% |
| Stock price CAGR | - | 39% | 51% | 149% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.52% of Sakar Healthcare Ltd (SAKAR) (down 0.34 pp QoQ). Market capitalisation was ₹1,835 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2017.
Largest disclosed public shareholders in Jun 2026: Tata Capital Healthcare Fund ii 10.38%, Hbm Healthcare Investments (Cayman) Ltd 6.74%, Cobra India (Mauritius) Limited 3.94%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.52% | - | - | - | - |
| Mar 2026 | 52.86% | - | - | - | - |
| Dec 2025 | 52.86% | - | - | - | - |
| Sep 2025 | 52.86% | - | - | - | - |
| Jun 2025 | 52.86% | - | - | - | - |
| Mar 2025 | 53.58% | - | - | - | - |
| Dec 2024 | 53.58% | - | - | - | - |
| Sep 2024 | 53.15% | - | - | - | - |